DAWN
Day One Biopharmaceuticals, Inc. · Healthcare
Insiders sold $423K net in the last 90 days ·5 sellers, 0 buyers· latest Form 4 filed Feb 18, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$673K
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Apr 23, 2026
Merendino Lauren
Day One Biopharmaceuticals, Inc. (DAWN) has 18 SEC Form 4 filings (62 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Apr 23, 2026.
Inside the rolling window, 5 insiders at Day One Biopharmaceuticals, Inc. reported no open-market purchases and 9 open-market sales totaling $673K. Insiders have net sold $673K over the trailing 6 months. The most recent open-market filing is a sale of 5,814 shares by Chief Commercial Officer Merendino Lauren, dated Feb 17, 2026, worth $67K.
- Industry:Biotechnology
- CEO:Jeremy Bender
- Employees:181
- HQ:Brisbane, CA, US
- IPO:2021-05-27
| Source | |||||||
|---|---|---|---|---|---|---|---|
Merendino LaurenFirst in 3 months | Chief Commercial Officer | Sale | 5,814 | $67K | Feb 18 | +86.2% | SEC ↗ |
Bender JeremyFirst in 3 months | CHIEF EXECUTIVE OFFICER | Sale | 15,459 | $179K | Feb 18 | +86.2% | SEC ↗ |
York Charles N IIFirst in 3 months | COO and CFO | Sale | 6,065 | $70K | Feb 18 | +86.2% | SEC ↗ |
Dubow AdamFirst in 3 months | Gen Counsel & Secretary | Sale | 6,395 | $74K | Feb 18 | +86.2% | SEC ↗ |
VASCONCELLES MICHAELFirst filing | Head of Research and Dev. | Sale | 2,728 | $32K | Feb 18 | +86.2% | SEC ↗ |
Dubow AdamFirst filing | Gen Counsel & Secretary | Sale | 4,319 | $39K | Nov 18 | +151.2% | SEC ↗ |
York Charles N IIFirst filing | COO and CFO | Sale | 4,062 | $36K | Nov 18 | +151.2% | SEC ↗ |
Bender JeremyFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 15,894 | $142K | Nov 18 | +151.2% | SEC ↗ |
Merendino LaurenFirst filing | Chief Commercial Officer | Sale | 3,726 | $33K | Nov 18 | +151.2% | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does DAWN have?
Day One Biopharmaceuticals, Inc. (DAWN) has 18 SEC Form 4 filings (62 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Apr 23, 2026.
When was the most recent SEC Form 4 filing for DAWN?
The most recent Form 4 filing for DAWN on Tracefour is dated Apr 23, 2026.
What is the net insider flow at DAWN over the last 6 months?
Over the trailing 180 days, insiders at DAWN have net sold $673K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at DAWN in the current window?
Inside the rolling window, insiders at DAWN bought $0 and sold $673K based on SEC Form 4 filings.
Can I get alerts for DAWN insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Day One Biopharmaceuticals, Inc. (DAWN). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Day One Biopharmaceuticals, Inc. is in the Healthcare sector.